Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Phase 3 KEYNOTE-789 Study - Pemetrexed & Platinum +/- Pembro for TKI-Resistant, EGFRm, Metastatic Non-Squamous NSCLC"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
James Yang
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
James Yang
Login to view comments.
Click here to Login
